Showing results (221-230 of 236) with videos related to
Sort By:
Pageof 24
Transfusion|October 22, 2011
The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron storesRitchard G Cable, Whitney R Steele, Russell S Melmed, et al.The Journal of Clinical Endocrinology and Metabolism|September 1, 1995
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center studyC B Newman, S Melmed, P J Snyder, et al.The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trialS Petersenn, J Schopohl, A Barkan, et al.The Journal of Clinical Endocrinology and Metabolism|February 12, 2009
Guidelines for acromegaly management: an updateS Melmed, A Colao, A Barkan, et al.The Journal of Clinical Endocrinology and Metabolism|April 28, 2012
Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppressionS Tuvia, J Atsmon, S L Teichman, et al.Journal of Molecular Endocrinology|December 14, 2004
PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitroK Boelaert, R Yu, L A Tannahill, et al.European Journal of Endocrinology|December 3, 2005
Consensus statement: medical management of acromegalyS Melmed, F Casanueva, F Cavagnini, et al.The Journal of Clinical Endocrinology and Metabolism|September 24, 1998
Octreotide as primary therapy for acromegalyC B Newman, S Melmed, A George, et al.Journal of Endocrinological Investigation|April 2, 2004
Diagnosis and treatment of acromegaly complicationsA Giustina, F F Casanueva, F Cavagnini, et al.The Journal of Clinical Endocrinology and Metabolism|October 30, 2008
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trialM Boscaro, W H Ludlam, B Atkinson, et al.Pageof 24